Trials / Completed
CompletedNCT04005872
Clinical and Radiographic Evaluation of Nano Silver Fluoride Versus Calcium Hydroxide in Indirect Pulp Treatment
Clinical and Radiographic Evaluation of Nano Silver Fluoride Versus Calcium Hydroxide in Indirect Pulp Treatment of Deep Carious Second Primary Molars, Randomized Clinical Trial
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Cairo University · Academic / Other
- Sex
- All
- Age
- 4 Years – 7 Years
- Healthy volunteers
- Accepted
Summary
The management of deep carious lesions approaching a healthy pulp is considered a challenge to the dental practitioner. The conventional treatment of deep carious lesions requires the removal of all infected and affected dentin to avoid more cariogenic activity.
Detailed description
This study is designed to assess the clinical and radiographic effectivness of nano silver fluoride versus calcium hydroxide in an indirect pulp treatment of deep carious second primary molars. This clinical study is important because World Health Organization (WHO) has reported that school children experience to dental caries was 60-90% of worldwide (P. D. Garkoti et al., 2015). This clinical trial has potential benefits to patients where indirect pulp treatment preserves pulp vitality by partial caries removal without exposing pulp. Several materials have been used for indirect pulp technique including calcium hydroxide (Metalita M et al., 2016).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Nano Silver Fluoride | Nano silver fluoride (NSF) is a new material consisting of nano silver particles, chitosan and sodium fluoride. It is a bacteriostatic and bactericidal compound. |
| DRUG | Calcium hydroxide | Calcium hydroxide is a gold standard for indirect pulp capping which induces hard tissue. |
Timeline
- Start date
- 2019-10-01
- Primary completion
- 2022-11-05
- Completion
- 2022-11-30
- First posted
- 2019-07-02
- Last updated
- 2022-12-20
Locations
1 site across 1 country: Egypt
Source: ClinicalTrials.gov record NCT04005872. Inclusion in this directory is not an endorsement.